Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 3 records in total 3
    records per page

    Post discharge persistent symptoms after COVID-19 MESHD in rheumatic MESHD and musculoskeletal diseases MESHD

    Authors: Leticia Leon; Ines Perez-Sancristobal; Alfredo Madrid; Leticia Lopez Pedraza; Jose Ignacio Colomer; Sergio Lerma; Pia Lois; Arkaitz Mucientes; Luis Rodriguez-Rodriguez; Lydia Abasolo; Benjamin Fernandez-Gutierrez

    doi:10.1101/2021.03.08.21253120 Date: 2021-03-08 Source: medRxiv

    OBJECTIVESTo describe persistent symptoms and consequences in Rheumatic and Musculoskeletal diseases MESHD ( RMD MESHD) discharged from the hospital after Covid-19 MESHD; to assess the roll of autoimmune rheumatic diseases MESHD ( ARD MESHD) compared to and non-autoimmune rheumatic MESHD and musculoskeletal diseases MESHD (NARD) on persistent symptoms and consequences. METHODSWe performed a cross-sectional observational study. RMD MESHD attended at a rheumatology outpatient clinic in Madrid with Covid-19 MESHD that required hospital admission were included. The main outcomes were persistence of symptoms and health consequences related to Covid19 MESHD after discharge. Independent variable was RMD MESHD group ( ARD MESHD and NARD) and covariates were sociodemographic, clinical, and treatments. We ran a multivariable logistic regression model to assess the risk by RMD MESHD group on main outcomes. RESULTSWe included 105 patients and 51.5% had ARD MESHD. 68.57% reported at least one persistent symptom. The most frequent were dyspnea MESHD, fatigue MESHD, and chest pain MESHD. 31 patients had consequences. Lung damage was found in 11.4% of the patients, 18% had blood test abnormalities MESHD (10% lymphopenia MESHD), two died, one developed central retinal vein occlusion MESHD and one patient developed optic neuritis MESHD. 11 patients required readmission due to Covid-19 MESHD problems (16.7% ARD MESHD vs 3.9% NARD; p=0.053). No statistically significant differences by RMD MESHD groups were found in the final models. CONCLUSIONMany RMD MESHD patients have persistent symptoms, similar to other populations. This study also highlights that lung damage MESHD is the most frequent consequence. ARD MESHD compared to NARD does not seem to differ in terms of persistent symptoms or consequences, although ARD MESHD might have a greater number of readmissions due to Covid-19 MESHD.

    Myelin Oligodendrocyte Glycoprotein HGNC ( MOG HGNC) Antibody Disease in a 11-year-old child with COVID 19 infection

    Authors: Archana Khan; Hiren Panwala; Divya Ramadoss; Raju Khubchandani

    doi:10.21203/ Date: 2020-11-07 Source: ResearchSquare

    Optic Neuritis is the most common presentation of MOG HGNC MOG MESHD Antibody Disease ( MOG-AD MESHD MOG-AD HGNC). We share our experience with a 11-year-old boy who developed MOG HGNC associated Optic Neuritis MESHD temporally associated with SARS- CoV-2 infection MESHD. He responded well to intravenous methylprednisolone therapy followed by oral prednisolone. While various neurological and ophthalmological manifestations of COVID-19 MESHD have been described previously, there are few case reports of Optic neuritis MESHD associated with COVID-19 MESHD. Our case further supports the evidence to suggest that SARS CoV-2 is another such virus that triggers MOG HGNC-AD.

    COVID-19 MESHD ocular findings in paediatric population

    Authors: Celia Fernandez Alcalde; Maria Granados Fernandez; María Nieves Moreno; Susana Noval Martin

    doi:10.21203/ Date: 2020-11-04 Source: ResearchSquare

    Purpose To investigate and describe ocular findings in COVID-19 MESHD paediatric patients. Methods A total of 17 COVID-19 MESHD patients aged between 0 and 17 years old were recruited at the Paediatric Hospital of La Paz University Hospital (Madrid, Spain). A complete ophthalmological examination was performed in all patients.  Results Of 17 patients, 50% had a known COVID-19 MESHD previous exposure. PCR from nasopharyngeal swabs was positive in 35.29%, whereas IgM and/or IgG serology tests were positive in 81%. Clinical manifestations were: 6 COVID-19 MESHDassociated Paediatric Inflammatory Multisystem Syndrome MESHD (PIMS), 7 pneumonias MESHD and 2 cutaneous purpura and/or chilblains. Ocular findings were ocular hyperaemia MESHD (5 patients), as bilateral acute conjunctivitis MESHD (3 patients) or unilateral episcleritis MESHD (2 patients). Mean best corrected visual acuity was 1/1 in all tested cases. Only one patient, presenting unilateral optic neuritis MESHD, had visual symptoms as unilateral inferior temporal quadrantanopsy. Retinal involvement was found in one patient, where ocular fundus exam showed unilateral retinal vasculitis MESHD. Conclusion SARS-CoV-2 infection MESHD could produce ocular pathology in children, frequently presented weeks after the acute phase of the disease. We should take into account COVID-19 MESHD when performing differential diagnosis of children presenting with conjunctivitis MESHD, episcleritis MESHD, retinal vasculitis MESHD and/or optic neuritis MESHD, meanwhile this world-wide pandemic lasts.   

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.